SEARCH

SEARCH BY CITATION

References

  • 1
    Kann M, Gerlich WH. Hepatitis B. In: CollierL, BalowsA, SussmanM, eds. Microbiology and Microbial Infections. Vol. 1. 9th ed. Virology. London: Topley & Wilson, 1998; 745773.
  • 2
    Mahoney FJ, Kane M. Hepatitis B vaccine. In: PlotkinSA, OrensteinWA, eds. Vaccines. 3rd ed. Philadelphia: Saunders, 1999; 158181.
  • 3
    Mast EE, Alter MJ, Margolis HS. Strategies to prevent and control hepatitis B and C virus infections: a global perspective. Vaccine 1999; 17:17301733. MEDLINE
  • 4
    Carman WF, Zanetti AR, Karayiannis P, Waters J, Manzillo G, Tanzi E. Vaccine-induced escape mutant of hepatitis B virus. Lancet 1990; 336:325329. MEDLINE
  • 5
    Bahn A, Gerner P, Martine U, Bortolotti F, Wirth S. Detection of different viral strains of hepatitis B virus in chronically infected children after seroconversion from HBsAg to anti-HBs indicating viral persistence. J Hepatol 1997; 27:973978. MEDLINE
  • 6
    Carman WF. The clinical significance of surface antigen variants of hepatitis B virus. J Viral Hepat 1997; 4(suppl 1):1120. MEDLINE
  • 7
    Ghany MG, Ayola B, Villamil FG, Gish RG, Rojter S, Vierling JM. Hepatitis B virus S mutants in liver transplant recipients who were reinfected despite hepatitis B immune globulin prophylaxis. Hepatology 1998; 27:213222. MEDLINE
  • 8
    Protzer-Knolle U, Naumann U, Bartenschlager R, Berg T, Hopf U, Meyer-zum Büschenfelde KH. Hepatitis B virus with antigenically altered hepatitis B surface antigen is selected by high-dose hepatitis B immune globulin after liver transplantation. Hepatology 1998; 27:254263. MEDLINE
  • 9
    Waters JA, Kennedy M, Voet P, Hauser P, Petre J, Carman W. Loss of the common “A” determinant of hepatitis B surface antigen by a vaccine-induced escape mutant. J Clin Invest 1992; 90:25432547. MEDLINE
  • 10
    Modrow S, Hoflacher B, Mellert W, Erfle V, Wahren B, Wolf H. Use of synthetic oligopeptides in identification and characterization of immunological functions in the amino acid sequence of the envelope protein of HIV-1. J Acquir Immune Defic Syndr 1989; 2:2122. MEDLINE
  • 11
    Honorati MC, Dolzani P, Mariani E, Piacentini A, Lisignoli G, Ferrari C. Epitope specificity of Th0/Th2 CD4+ T-lymphocyte clones induced by vaccination with rHBsAg vaccine. Gastroenterology 1997; 112:20172027. MEDLINE
  • 12
    Barnaba V, Levrero M, Ruberti G, van- Dyke A, Perrone A, Musca A. In vitro anti-HBs antibody synthesis from anti-hepatitis B vaccine recipients. Clin Exp Immunol 1987; 70:283288. MEDLINE
  • 13
    Böcher WO, Herzog HS, Herr W, Heermann K, Gerken G, Meyer-zum Büschenfelde KH, Löhr HF. Regulation of the neutralizing anti-hepatitis B surface (HBs) antibody response in vitro in HBs vaccine recipients and patients with acute or chronic hepatitis B virus (HBV) infection. Clin Exp Immunol 1996; 105:5258. MEDLINE
  • 14
    Salazar M, Deulofeut H, Granja C, Deulofeut R, Yunis DE, Marcus BD. Normal HBsAg presentation and T-cell defect in the immune response of nonresponders. Immunogenetics 1995; 41:366374. MEDLINE
  • 15
    Celis E, Ou D, Otvos L. Recognition of hepatitis B surface antigen by human T lymphocytes. Proliferative and cytotoxic responses to a major antigenic determinant defined by synthetic peptides. J Immunol 1988; 140:18081815. MEDLINE
  • 16
    Howard CR, Allison LM. Hepatitis B surface antigen variation and protective immunity. Intervirology 1995; 38:3540. MEDLINE
  • 17
    Magnius LO, Norder H. Subtypes, genotypes and molecular epidemiology of the hepatitis B virus as reflected by sequence variability of the S-gene. Intervirology 1995; 38:2434. MEDLINE
  • 18
    Weinberger KM, Kreuzpaintner EA, Hottenträger B, Neifer S, Jilg W. Mutations in the s-gene of hepatitis B virus (HBV) isolates from chronic carriers with anti-HBc as the only serologically marker of HBV infection. In: RizzettoM, PurcellRH, GerinJL, VermeG, eds. Viral Hepatitis and Liver Disease. Torino: Edizioni Minerva Medica, 1997; 138143.
  • 19
    Weinberger KM, Bauer T, Böhm S, Jilg W. High genetic variability of the group-specific a-determinant of hepatitis B surface antigen (HBsAg) and the corresponding fragment of the viral polymerase in chronic carriers lacking detectable HBsAg in serum. J Gen Virol 2000; 1:11651174.
  • 20
    Sinigaglia F, Guttinger M, Kilgus J, Doran DM, Matile H, Etlinger H, Trzeciak A, et al. A malaria T-cell epitope recognized in association with most mouse and human MHC class II molecules. Nature 1988; 336:778780. MEDLINE
  • 21
    Böcher WO, Herzog HS, Schlaak J, Meyer-zum Büschenfelde KH, Löhr HF. Kinetics of hepatitis B surface antigen-specific immune responses in acute and chronic hepatitis B or after HBs vaccination: stimulation of the in vitro antibody response by interferon gamma. Hepatology 1999; 29:238244. MEDLINE
  • 22
    Sylvan SP, Hellstrom UB. HBsAg-induced interferon-gamma secretion in T cells from asymptomatic HBsAg carriers and HB-immune donors in vitro. Immunology 1990; 70:197202. MEDLINE
  • 23
    Tsutsui H, Mizoguchi Y, Morisawa S. There is no correlation between function and lymphokine production of HBs-antigen-specific human CD4(+)-cloned T cells. Scand J Immunol 1991; 34:433444. MEDLINE
  • 24
    Milich DR, McLachlan A, Chisari FV, Kent SB, Thorton GB. Immune response to the pre-S(1) region of the hepatitis B surface antigen (HBsAg): a pre-S(1)-specific T cell response can bypass nonresponsiveness to the pre-S(2) and S regions of HBsAg. J Immunol 1986; 137:315322. MEDLINE
  • 25
    Jilg W, Schmidt M, Deinhardt F. Persistence of specific antibodies after hepatitis B vaccination. J Hepatol 1988; 6:201213. MEDLINE
  • 26
    Melegari M, Scaglioni PP, Wands JR. Hepatitis B virus mutants associated with 3TC and famciclovir administration are replication defective. Hepatology 1994; 27:628633.
  • 27
    Pichoud C, Seignères B, Wang Z, Trépo C, Zoulim F. Transient selection of a hepatitis B virus polymerase gene mutant associated with a decreased replication capacity and famciclovir resistance. Hepatology 1999; 29:230237. MEDLINE
  • 28
    Zoulim F, Trépo C. Drug therapy for chronic hepatitis B antiviral efficacy and influence of hepatitis B virus polymerase mutations on the outcome of therapy. J Hepatol 1998; 29:151116. MEDLINE